Latest & greatest articles for nsaids

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nsaids or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on nsaids and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for nsaids

21. Baker's cyst: Paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs)

Baker's cyst: Paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs) Paracetamol and NSAIDS | Prescribing information | Baker's cyst | CKS | NICE Search CKS… Menu Paracetamol and NSAIDS Baker's cyst: Paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs) Last revised in May 2020 Paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs) For prescribing information on paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs), see the CKS topics on and . © .

2018 NICE Clinical Knowledge Summaries

22. Ankylosing spondylitis: Oral nonsteroidal anti-inflammatory drugs (NSAIDs)

Ankylosing spondylitis: Oral nonsteroidal anti-inflammatory drugs (NSAIDs) Oral NSAIDs | Prescribing information | Ankylosing spondylitis | CKS | NICE Search CKS… Menu Oral NSAIDs Ankylosing spondylitis: Oral nonsteroidal anti-inflammatory drugs (NSAIDs) Last revised in May 2019 Oral nonsteroidal anti-inflammatory drugs (NSAIDs) What issues should I consider before prescribing a standard or coxib nonsteroidal anti-inflammatory drug? For more information on prescribing nonsteroidal anti (...) -inflammatory drugs (NSAIDs) and coxibs, see the CKS topic on . © .

2018 NICE Clinical Knowledge Summaries

23. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study Full Text available with Trip Pro

Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study To assess the non-inferiority of vonoprazan to lansoprazole for secondary prevention of non-steroidal anti-inflammatory drug (NSAID)-induced peptic ulcer (PU) and the safety of vonoprazan during extended use.A phase 3, 24-week, multicenter, randomised, double-blind (DB), active-controlled study, followed by a phase 3, ≥28 week, multicenter (...) , single-blind, parallel-group extension study (EXT) in outpatients (n=642) receiving long-term NSAID therapy who are at risk of PU recurrence. The patients received vonoprazan (10 mg or 20 mg) or lansoprazole 15 mg once daily. For DB, non-inferiority of the proportion of patients with recurrent PU within 24 weeks was analysed by Farrington and Manning test (significance level 2.5%, non-inferiority margin 8.3%; primary endpoint), recurrent PU within 12 weeks, bleeding and time-to-event of PU (secondary

2017 EvidenceUpdates

24. Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. Full Text available with Trip Pro

Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. Pain is a common feature of childhood and adolescence around the world, and for many young people, that pain is chronic. The World Health Organization guidelines for pharmacological treatments for children's persisting pain acknowledge that pain in children is a major public health concern of high significance in most parts of the world. While in the past pain was largely dismissed (...) ) is a major health concern. Chronic pain (that is pain lasting three months or longer) can arise in the paediatric population in a variety of pathophysiological classifications (nociceptive, neuropathic, or idiopathic) from genetic conditions, nerve damage pain, chronic musculoskeletal pain, and chronic abdominal pain, as well as for other unknown reasons.Non-steroidal anti-inflammatory drugs (NSAIDs) are used to treat pain, reduce fever, and for their anti-inflammation properties. They are commonly used

2017 Cochrane

25. Non-steroidal anti-inflammatory drugs (NSAIDs) for cancer-related pain in children and adolescents. Full Text available with Trip Pro

Non-steroidal anti-inflammatory drugs (NSAIDs) for cancer-related pain in children and adolescents. Pain is a common feature of childhood and adolescence around the world, and for many young people, that pain is chronic. The World Health Organization (WHO) guidelines for pharmacological treatments for persisting pain in children acknowledge that pain in children is a major public health concern of high significance in most parts of the world. Views on children's pain have changed over time (...) treatments, or mucositis. However, this review focused on pain caused directly by the tumour itself such as nerve infiltration, external nerve compression, and other inflammatory events.Non-steroidal anti-inflammatory drugs (NSAIDs) are used to treat pain, reduce fever, and for their anti-inflammatory properties. They are commonly used within paediatric pain management. NSAIDs are currently licensed for use in western countries, however not approved for infants aged under three months. Primary adverse

2017 Cochrane

26. NSAIDs for Chronic Low Back Pain. (Abstract)

NSAIDs for Chronic Low Back Pain. Are nonsteroidal anti-inflammatory drugs (NSAIDs) associated with greater pain relief than placebo, other drugs, and nondrug treatments for patients with chronic low back pain?Compared with placebo, NSAIDs are associated with a small but significant improvement in pain and disability in patients with chronic low back pain, although this difference became nonsignificant when studies with high risk for bias were excluded. The associated benefits were smaller than

2017 JAMA Controlled trial quality: uncertain

27. Unborn children still exposed to NSAIDs

Unborn children still exposed to NSAIDs Prescrire IN ENGLISH - Spotlight ''In the April issue of Prescrire International: unborn children still exposed to NSAIDs'', 1 April 2017 {1} {1} {1} | | > > > In the April issue of Prescrire International: unborn children still exposed to NSAIDs Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight In the April (...) issue of Prescrire International: unborn children still exposed to NSAIDs FREE DOWNLOAD In the Adverse Effects section of the April edition: results of a French study showing that around 5% of unborn children in France are exposed to prescribed NSAIDs, including about 1% from the 6th month of pregnancy. And these numbers exclude self-medication. Authorities need to send out a stronger message: "NEVER USE NSAIDs DURING PREGNANCY". Full text available for free download. Summary A study based on data

2017 Prescrire

28. NSAIDs are Caspase Inhibitors Full Text available with Trip Pro

NSAIDs are Caspase Inhibitors Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used drugs in the world. While the role of NSAIDs as cyclooxygenase (COX) inhibitors is well established, other targets may contribute to anti-inflammation. Here we report caspases as a new pharmacological target for NSAID family drugs such as ibuprofen, naproxen, and ketorolac at physiologic concentrations both in vitro and in vivo. We characterize caspase activity in both in vitro (...) and in cell culture, and combine computational modeling and biophysical analysis to determine the mechanism of action. We observe that inhibition of caspase catalysis reduces cell death and the generation of pro-inflammatory cytokines. Further, NSAID inhibition of caspases is COX independent, representing a new anti-inflammatory mechanism. This finding expands upon existing NSAID anti-inflammatory behaviors, with implications for patient safety and next-generation drug design.Copyright © 2017 Elsevier Ltd

2017 Cell chemical biology

29. Topical NSAIDs versus Opioids for Acute Musculoskeletal Pain: A Review of the Clinical Effectiveness

Topical NSAIDs versus Opioids for Acute Musculoskeletal Pain: A Review of the Clinical Effectiveness Topical NSAIDs versus Opioids for Acute Musculoskeletal Pain: A Review of the Clinical Effectiveness | CADTH.ca Find the information you need Topical NSAIDs versus Opioids for Acute Musculoskeletal Pain: A Review of the Clinical Effectiveness Topical NSAIDs versus Opioids for Acute Musculoskeletal Pain: A Review of the Clinical Effectiveness Published on: January 30, 2017 Project Number: RC0844 (...) -000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of topical NSAIDs versus opioids for the treatment of acute musculoskeletal pain? Key Message Compared with placebo, topical NSAIDs were effective in reducing pain from acute musculoskeletal conditions, such as sprains, strains or sport injuries. Adverse events were rare and were usually related to skin reactions. No evidence regarding

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

30. Musculoskeletal Strains and Sprains - Guidelines for Prescribing NSAIDs

Musculoskeletal Strains and Sprains - Guidelines for Prescribing NSAIDs Musculoskeletal Strains and Sprains - Guidelines for Prescribing NSAIDs - medSask Home - College of Pharmacy and Nutrition - University of Saskatchewan Toggle Menu Search the U of S Search Musculoskeletal Strains and Sprains - Guidelines for Prescribing NSAIDs Musculoskeletal pain arises from the muscles, bones, joints, and connective tissue. The musculoskeletal system includes the muscles, tendons, ligaments, cartilage (...) with the differential assessment. Diabetes - expect longer healing times Stroke - could cause one-sided weakness Cancer - pain with no apparent cause could be a sign of worsening cancer control in a patient with a history of cancer Bleeding disorders - avoid NSAIDs in these patients History of DVT - significant leg or calf pain may be a sign of a DVT, especially in a patient who has had a prior DVT GI disorders - may choose to avoid NSAIDs in these patients Cardiovascular disorders - may choose to avoid NSAIDs

2017 medSask

32. Nonsteroidal anti-inflammatory drug (NSAID) toxicity - emergency management

Nonsteroidal anti-inflammatory drug (NSAID) toxicity - emergency management

2017 DynaMed Plus

35. NSAIDs - prescribing issues

NSAIDs - prescribing issues NSAIDs - prescribing issues | Topics A to Z | CKS | NICE Search CKS… Menu NSAIDs - prescribing issues NSAIDs - prescribing issues Last revised in August 2019 Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit cyclo-oxygenase (COX) enzymes Management Background information NSAIDs - prescribing issues: Summary Nonsteroidal anti-inflammatory drugs (NSAIDs) have analgesic, antipyretic and, at higher doses, anti-inflammatory actions. NSAIDs inhibit prostaglandin (...) synthesis by reversibly inhibiting cyclo-oxygenase (COX) enzymes — the two main types of COX enzyme are COX-1 and COX-2, which have different physiological functions. COX-1 produces prostaglandins that help to maintain gastric mucosal integrity and platelet-initiated blood clotting. Inhibition is thought to be responsible for gastrointestinal toxicity. COX-2 produces prostaglandins that mediate pain and inflammation. Inhibition is thought to be responsible for the anti-inflammatory action of NSAIDs

2017 NICE Clinical Knowledge Summaries

36. Safety considerations for NSAIDs

Safety considerations for NSAIDs Vol 24. DTB: Vol 24, No 2 - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DTB: Vol 24, No 2 DTB: Vol 24, No 2 Content tools Share it Safety considerations for NSAIDs The gastrointestinal, cardiovascular, and renal adverse effects of NSAIDs are related to the total daily dose and may appear less than 15 days from the start of treatment. The safest NSAIDs are ibuprofen and naproxen, whether used alone (...) . Although gastrointestinal risk can be countered using gastric protectors, there is no concomitant drug therapy for cardiovascular risk. The results of this review reveal an overuse of celecoxib and etoricoxib in Navarre. NSAIDs in combination with proton pump inhibitors (PPIs) should be used with caution, since PPIs are not indicated for all patients requiring NSAIDs. Furthermore, the combination of these drugs may result in incorrect dosages. Authors: Isabel Aranguren. Pharmacist. Navarre Health

2016 Drug and Therapeutics Bulletin of Navarre (Spain)

37. Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy Using an NSAID for Other Pain Conditions: A Double-Blind Crossover Study (Abstract)

Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy Using an NSAID for Other Pain Conditions: A Double-Blind Crossover Study To evaluate pregabalin's efficacy and safety versus placebo to reduce pain in patients with diabetic peripheral neuropathy (DPN) using a concomitant nonsteroidal anti-inflammatory drug.In a randomized, double-masked, 14-week, 2-period, crossover study, patients with painful DPN using a nonsteroidal anti-inflammatory drug for non-DPN-related pain received

2016 EvidenceUpdates Controlled trial quality: predicted high

38. Nonsteroidal anti-inflammatory drugs (NSAIDs): avoid cox-2 inhibitors, diclofenac and high-dose ibuprofen

Nonsteroidal anti-inflammatory drugs (NSAIDs): avoid cox-2 inhibitors, diclofenac and high-dose ibuprofen Prescrire IN ENGLISH - Spotlight ''Nonsteroidal anti-inflammatory drugs (NSAIDs): avoid cox-2 inhibitors, diclofenac and high-dose ibuprofen'', 1 January 2016 {1} {1} {1} | | > > > Nonsteroidal anti-inflammatory drugs (NSAIDs): avoid cox-2 inhibitors, diclofenac and high-dose ibuprofen Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |  (...)  |   |   |   |   |   |   |  Spotlight Nonsteroidal anti-inflammatory drugs (NSAIDs): avoid cox-2 inhibitors, diclofenac and high-dose ibuprofen When pain medication is required, paracetamol (alias acetaminophen) is the reference drug. Among the nonsteroidal anti-inflammatories (NSAIDs), naproxen or ibuprofen (not exceeding 1200 mg a day) are the drugs that carry the least exposure to cardiac disorders. When pain medication is needed

2016 Prescrire

39. Systematic review: Topical NSAIDs significantly reduces pain in adults with acute musculoskeletal injuries

Systematic review: Topical NSAIDs significantly reduces pain in adults with acute musculoskeletal injuries Topical NSAIDs significantly reduces pain in adults with acute musculoskeletal injuries | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Topical NSAIDs significantly reduces pain in adults with acute musculoskeletal injuries Article Text Therapeutics/Prevention Systematic review Topical NSAIDs significantly reduces pain in adults

2016 Evidence-Based Medicine

40. NSAIDs: Inflamed effects on inflammation?

NSAIDs: Inflamed effects on inflammation? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,000 family physicians, family medicine residents and medical students in Alberta. Established over fifty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca March 29, 2016 NSAIDs (...) : Inflamed effects on inflammation? Clinical Question: Do non-steroidal anti-inflammatory drugs (NSAIDs) reduce swelling and inflammation in acute injury? Bottom Line: Randomized Controlled Trials (RCTs) of NSAIDs effect on musculoskeletal injury swelling show highly inconsistent results: Some slight improvements (2-11%), some slight worsening (8%) and most no effect. It is unlikely NSAIDs have any reliable effect on acute injury swelling but they do improve pain for ~1 in 4 over one week. Evidence

2016 Tools for Practice